ArticleAmerican journal of ophthalmology case reports2021
A case of ulcerative colitis associated with teprotumumab treatment for thyroid eye disease.
Article in American journal of ophthalmology case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Infliximab-Responsive Severe Ulcerative Colitis With Pyoderma Gangrenosum After IL-6 and IGF-1 Blockade.ACG case reports journal · 2026Article
- Time to improvement following teprotumumab treatment of thyroid eye disease: real world experience.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Article
- Teprotumumab in the management of thyroid eye disease mechanistic insights and adverse reactions: a comprehensive review.Frontiers in endocrinology · 2025Review
- Graves disease: latest understanding of pathogenesis and treatment options.Nature reviews. Endocrinology · 2024Review
- Data mining and analysis of adverse event signals associated with teprotumumab using the Food and Drug Administration adverse event reporting system database.International journal of clinical pharmacy · 2024Article
- Teprotumumab-Related Adverse Events in Thyroid Eye Disease: A Multicenter Study.Ophthalmology · 2024Observational
- Immunological Processes in the Orbit and Indications for Current and Potential Drug Targets.Journal of clinical medicine · 2023Review
- The Adverse Effects Profile of Teprotumumab.The Journal of clinical endocrinology and metabolism · 2023Review
- Current concepts regarding Graves' orbitopathy.Journal of internal medicine · 2022Review
- Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease.The Journal of clinical endocrinology and metabolism · 2022Review
- Teprotumumab for Graves' orbitopathy and ototoxicity: moving problems from eyes to ears?Journal of endocrinological investigation · 2022Article
- Teprotumumab-associated chronic hearing loss screening and proposed treatments.BMJ case reports · 2022Article
- Efficacy and Safety of Teprotumumab in Thyroid Eye Disease.Therapeutics and clinical risk management · 2021Review
- Updates on the understanding and management of thyroid eye disease.Therapeutic advances in ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo present a case of ulcerative colitis associated with teprotumumab treatment for thyroid eye disease. OBSERVATIONS: A 46-year-old Indian female was treated with teprotumumab (Tepezza) for severe thyroid eye disease within 9 months of diagnosis. The patient noted progression of her disease on oral prednisone and demonstrated severe, debilitating proptosis accompanied by eye ache and dry eyes. After 5 infusions of teprotumumab over a four-month period, the patient developed bloody diarrhea and fecal urgency. These symptoms progressively worsened and after two additional treatments, she underwent a colonoscopy. This confirmed the diagnosis of ulcerative colitis (UC). Treatment with teprotumumab was halted prior to the administration of the 8th infusion; however, the patient continued to have severe gastrointestinal symptoms two months after her last treatment. CONCLUSIONS AND IMPORTANCE: Teprotumumab is an insulin-like growth factor-1 receptor (IGF-1R) inhibitor demonstrated to improve proptosis in patients with active thyroid eye disease. Most adverse events reported are mild or moderate in severity; however, inflammatory bowel disease (IBD) is a serious adverse event that can develop as a result of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.